# THE CONFIDENCE TO KNOW BLEEDING WILL STOP

Intraoperative reliability and consistency. Helping to improve patient outcomes.





Veriset<sup>™</sup> hemostatic patch




#### SAFETY FOR YOUR PATIENTSTS<sup>2</sup>

#### Increased patient safety<sup>2</sup>

Unlike any other high-efficacy hemostat, Veriset<sup>™</sup> hemostatic patch is 100% free of human or animal components,<sup>2</sup> eliminating the risk of viral transmission.

#### **Oxidised Regenerated Cellulose**

- 3-D pattern allows for blood absorption.
- Known to promote hemostasis via a reduction in blood pH.
- Acts as a tamponade.



#### **Trilysine**

 Combines together with the PEG to form a hydrogel barrier.


#### Reactive Polyethylene Glycol (PEG)

- Proprietary sealant technology.
- Effective barrier to blood flow.
- Adheres the patch to the bleeding site.

## Universal Use:<sup>Ω</sup> Effective in cases of inhibited coagulation and independent of clotting ability<sup>3</sup>











#### **Placement**

- PEG side (darker) of the Veriset<sup>™</sup> hemostatic patch placed against the bleeding site.<sup>2</sup>
- Blood wicks into the patch and it becomes compliant.

#### **Pressure**

• The oxidised regenerated cellulose within the patch absorbs blood and initiates the coagulation process by a reduction in blood pH.

#### **Polymerisation**

- Polymer components cross-link to form an impenetrable barrier (hydrogel). It then adheres to the bleeding site.
- Coagulation components concentrate and accelerate hemostasis.

#### Hemostasis

Hemostasis is achieved in ~1 minute.

#### **Absorption**


Veriset<sup>™</sup> hemostatic patch is fully absorbed in ~4 weeks.²

"I'm very impressed with the level of blood that can be addressed."

MR. M. STECHMAN (CONSULTANT ENDOCRINE SURGEON, CARDIFF, UK)

#### IMPRESSIVE CLINICAL PERFORMANCE<sup>1</sup>

#### Fast and consistent, allowing hemostasis in ~one minute<sup>†,1</sup>




<sup>&</sup>lt;sup>†</sup> Compared with other available hemostatic products studied in different anatomical locations.

#### "Better than TachoSil™ in hemostasis and in handling."

MR. M. STECHMAN (CONSULTANT ENDOCRINE SURGEON, CARDIFF, UK)

### 66% faster than TachoSil<sup>™</sup> fibrin patch¹ (p<0.001)



**Chart 1:** Percentage of patients reaching hemostasis in a multicentre randomised clinical trial for bleeding management in hepatic surgery; Veriset<sup>™</sup> hemostatic patch: n=32; TachoSil<sup>™</sup> patch: n=18).



#### **EASY TO USE<sup>2</sup>**

#### No special storage requirements guarantees easy access when needed<sup>2</sup>

Refer to the Instructions for Use (IFU) for full details.

#### Ready to use in both open and laparoscopic procedures with no preparation time<sup>2</sup>

Please refer to the IFU for complete indications and application instructions.

- Open the foil pouch, ensuring you use the Veriset<sup>™</sup> hemostatic patch within 60 minutes after opening. The patch should not be hydrated prior to placement.
- Place the darker side (striped side) of Veriset<sup>™</sup> hemostatic patch on the bleeding site, extending ~1–2 cm beyond the bleeding site (the patch may be cut as necessary for the desired application).
- Hold firmly in place to ensure proper adherence to the bleeding site. After 30 seconds, discontinue pressure and inspect the bleeding site. Do not reposition the patch after holding in place for >5 seconds..
- If bleeding has not stopped, reapply pressure and reassess after 30 seconds. If hemostasis is not obtained, additional patches can be applied over the existing material or as replacement for the initial material.
- Nonhydrated portions of Veriset<sup>™</sup> hemostatic patch can be removed by cutting along the edges or be adhered to the surface by hydrating with saline and applying pressure.
- Do not remove Veriset<sup>™</sup> hemostatic patch at the end of surgery. The implant will absorb after ~28 days.

# INTRODUCING NEW HEMOSTATIC TECHNOLOGY

Designed to help you achieve hemostasis quickly and consistently<sup>1</sup>

- Fast and consistent¹
- Increased patient safety<sup>2</sup>
- Universal use<sup>¥,3</sup>
- Ease of use<sup>1,2</sup>
- Potential cost savings<sup>4,5</sup>





#### **VERISET™ HEMOSTATIC PATCH**

# Potentially lowering the costs associated with surgery and postoperative patient management<sup>4,5</sup>

"Bleeding is detrimental and costly... Prevention of bleeding and transfusion can be expected to have tremendous effects on reallocation of resources."

"Peri-operative blood loss during liver surgeries may add significant burden to hospital resources and costs." 5

"Patients with peri-operative blood loss possibly tend to stay significantly longer in the hospital and may have a higher mortality rate compared to those who do not experience peri-operative blood loss." 5

ORDER CODE	SIZE	<b>BOX QUANTITY</b> (6 UNITS PER BOX)
HP0204E1	2 cm x 4 cm (8 cm²)	1/Bx
HP0204E	2 cm x 4 cm (8 cm²)	6/Bx
HP0505E1	5 cm x 5 cm (25 cm²)	1/Bx
HP0505E	5 cm x 5 cm (25 cm²)	6/Bx
HP0510E1	5 cm x 10 cm (50 cm²)	1/Bx
HP0510E	5 cm x 10 cm (50 cm²)	6/Bx
HP0816E1	8 cm x 16 cm (128 cm²)	1/Bx
HP0816E	8 cm x 16 cm (128 cm²)	6/Bx
HP0204CVE	2 cm x 4 cm Cutting Template	6/Bx

#### For more information or to set up a product demonstration, contact your local Medronic representative.

#### REFERENCES

- Öllinger R, et al. A multicenter, randomized clinical trial comparing the Veriset™ haemostatic patch with fibrin sealant for the management of bleeding during hepatic surgery. HPB (Oxford), Epub Dec. 27, 2012. doi: 10.1111/hpb.12009 [epub ahead of print].
- 2. Veriset™ haemostatic patch instructions for use and product specifications. 2014.
- Sponsored preclinical study assessing CV and PV models on animals with inhibited platelet activity (heparin, aspirin, Plavix<sup>TM\*</sup>). 2010.
- Shander A. Financial and clinical outcomes associated with surgical bleeding complications. Surgery. 2007;142(4 Suppl):S20-525.
- Parikh N, Hashemi L, Morseon M, Ally A. Resource utilization and costs associated with perioperative blood loss during liver surgeries. A retrospective data analysis in the United States, Covidien USA, Covidien UK, IHPBA. 2012.
- 6. Baxter Floseal™\* haemostatic matrix instructions for use. 2012.

- 7. Takeda TachoSil™\* fibrin sealant patch instructions for use. 2009.
- $8.\ Ethicon\ Evicel^{\text{TM}*}\ fibrin\ sealant\ instructions\ for\ use.\ 2009.$
- $9.\,Ethicon\,Surgicel^{\intercal m*}\,absorbable\,haemostat\,instructions\,for\,use.\,2010.$
- $10.\ Pfizer\ Gelfoam^{\text{TM}*}\ gelatin\ sponge\ instructions\ for\ use.\ 2012.$

 $\Omega$ Based on serum plasma morphology.

- $\ \ \texttt{¥ Effective despite coagulation/clotting deficiency (based on serum plasma morphology)}.$
- \* According to TachoSil  $\ensuremath{^{\text{TM}}}$  prescribing information.





For more information, please visit medtronic.eu/product-catalog

IMPORTANT: Please refer to the package insert for complete instructions, contraindications, warnings and precautions